White House health advisor concerned coronavirus vaccine immunity won’t last forever

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Disease (NIAID) and White House public health advisor, is concerned that a potential vaccine to protect against the novel coronavirus, COVID-19, may not deliver long-term immunity.

Fauci relayed his concerns in an interview with Howard Bauchner, editor of JAMA. Specifically, Fauci said he is “cautiously optimistic” about a vaccine, but that it will take several months before scientists can prove a vaccine works.

There are a handful of ongoing clinical trials to test the efficacy of a COVID-19 vaccine. Scientists hope to have a vaccine by the beginning of 2021, CNBC reported. Fauci is hopeful the U.S. will have several hundred million doses available by then.

“When you look at the history of coronaviruses, the common coronaviruses that cause the common cold, the reports in the literature are that the durability of immunity that’s protective ranges from three to six months to almost always less than a year,” Fauci said. “That’s not a lot of durability and protection.”

Further, there are still major questions about how immune systems respond to the virus once a person is exposed, CNBC reported.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.